Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant comparison of TCH versus TH followed by FECH in HER2-positive breast cancer
ChiCTR1900021068Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, carboplatin, trastuzumab, epirubicin and cyclophosphamide in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological complete remission rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900021068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021068.